VectorB2B provides highly qualified services in drug discovery and development from the bench to bedside (B2B)
Beside our internal teams, we rely on a strong and complementary set of academic and industrial partners renowned within the Portuguese Health Sector. Together, we form a robust platform of knowledge and innovation, providing cutting-edge technology and expertise, delivered by a team of excellence.
The combination of CDMO/CRO services as a One-Stop Shop leads to cost and time-efficient solutions.
Our expertise comprises discovery, toxicology, contract manufacturing
and clinical services:
Drug Discovery
VectorB2B Discovery’s services span across multiple therapeutic areas and classes of molecules.
VectorB2B offers the scientific expertise and technical capabilities required to support your drug discovery program from target identification all the way through IND submission. Our scientific team bring together the expertise of top Portuguese scientists, providing the best services in Discovery.
Moreover, from your initial contact and through every milestone of your project, you can expect frequent and proactive communication from a dedicated project manager.
We provide fully flexible and tailored solutions to meet your needs, time schedule and budget. In fact, VectorB2B can provide stand-alone projects or fully integrated drug discovery support to advance your product to the market.
- High throughput screening using robotized system
- Gene expression profiling & manipulation
- In vitro target validation
- In vivo target validation
- Access to biobank samples
- Phage Display
- In vitro Blood Brain Barrier (BBB) permeability evaluation
- In vitro Intestinal permeability evaluation
- Cellular and tissue biophysics
- Molecular biophysics
- In vitro models & in vitro assays
- In vivo models (rodents & non-rodents) for different therapeutic areas
- Antibodies
- ADME-TOX studies (in vitro; in vivo)
- Immunogenicity assessment
Other services beside Drug Discovery
Toxicology
VectorB2B Toxicology Unit offers state-of-the-art facilities and scientific expertise. We offer dedicated preclinical services in Toxicology (GLP and non-GLP), such as:
- Genotoxicity
- Safety Pharmacology
- Pharmacokinetics/Pharmacodynamics
- Acute Toxicology
- Sub-acute Toxicology
- Chronic Toxicology
- Sub-chronic Toxicology
- Other in vitro assays
Contract Manufacturing
At VectorB2B, our expert technical teams are dedicated to optimal process development and manufacturing (GMP and non-GMP) always focused on the customization for your product. Our primary goal is to offer you a true one-stop-shop CDMO service, with full customization for each step of your process.
- Process development
- Tech-transfer
- GMP manufacturing
- Analytical methods development and validation
- Formulation development
- Quality control
- Batch release
- Drug substance manufacturing
- Drug product manufacturing
Clinical Studies
VectorB2B is a full-service CRO with privileged access to a broad network of clinical sites in Portugal and recognized KOLs across different therapeutic areas.
The collaborative network of academic and industrial partners within the Portuguese Health sector framework ensures VectorB2B the flexibility and competitiveness of a small organization along with the experience of a global CRO.
- Strategic consulting
- Clinical solutions
- Medical and scientific services
- Regulatory strategy
- Medical writing
- Training services
Please contact us at: info@vectorb2b.com
Visit our new website: https://vectorb2b.com/
About Drug Discovery Innovation Programme 2023
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2023 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2023 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.